# DAFNA Capital Management LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1389933. Source: https://holderbook.com/funds/1389933-dafna-capital-management-llc/

- Reported value: $524.4M
- Positions: 88
- Weight of the ten largest: 56.2%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $105.4M | 562,630 | 20.1% | 23 |
| SPDR SERIES TRUST | [XBI](https://holderbook.com/stocks/XBI/) | $31.1M | 196,505 | 5.9% | 18 |
| COMPASS PATHWAYS PLC | [CMPS](https://holderbook.com/stocks/CMPS/) | $28.5M | 2,011,952 | 5.4% | 12 |
| STEREOTAXIS INC | [STXS](https://holderbook.com/stocks/STXS/) | $23.5M | 13,680,554 | 4.5% | 31 |
| NEKTAR THERAPEUTICS | [NKTR](https://holderbook.com/stocks/NKTR/) | $22.2M | 318,380 | 4.2% | 5 |
| DENALI THERAPEUTICS INC | [DNLI](https://holderbook.com/stocks/DNLI/) | $19.0M | 739,014 | 3.6% | 6 |
| IDEAYA BIOSCIENCES INC | [IDYA](https://holderbook.com/stocks/IDYA/) | $18.5M | 497,240 | 3.5% | 24 |
| ATRICURE INC | [ATRC](https://holderbook.com/stocks/ATRC/) | $16.7M | 597,431 | 3.2% | 31 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $15.1M | 250,772 | 2.9% | 31 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $14.7M | 171,998 | 2.8% | 20 |
| ARCUS BIOSCIENCES INC | [RCUS](https://holderbook.com/stocks/RCUS/) | $13.6M | 441,829 | 2.6% | 26 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $12.9M | 48,469 | 2.5% | 1 |
| NEUROCRINE BIOSCIENCES INC | [NBIX](https://holderbook.com/stocks/NBIX/) | $9.7M | 57,769 | 1.9% | 31 |
| AXOGEN INC | [AXGN](https://holderbook.com/stocks/AXGN/) | $9.7M | 208,960 | 1.8% | 19 |
| INSULET CORP | [PODD](https://holderbook.com/stocks/PODD/) | $9.4M | 61,870 | 1.8% | 10 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $9.2M | 226,819 | 1.8% | 18 |
| BICARA THERAPEUTICS INC | [BCAX](https://holderbook.com/stocks/BCAX/) | $8.5M | 284,955 | 1.6% | 7 |
| ISHARES TR | [IBB](https://holderbook.com/stocks/IBB/) | $8.1M | 42,595 | 1.5% | 31 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $7.3M | 335,255 | 1.4% | 25 |
| MAPLIGHT THERAPEUTICS INC | [MPLT](https://holderbook.com/stocks/MPLT/) | $6.1M | 171,006 | 1.2% | 3 |
| LARIMAR THERAPEUTICS INC | [LRMR](https://holderbook.com/stocks/LRMR/) | $6.1M | 2,008,164 | 1.2% | 25 |
| CENTURY THERAPEUTICS INC | [IPSC](https://holderbook.com/stocks/IPSC/) | $5.9M | 2,400,458 | 1.1% | 21 |
| DEXCOM INC | [DXCM](https://holderbook.com/stocks/DXCM/) | $5.8M | 86,279 | 1.1% | 31 |
| IMMUNOVANT INC | [IMVT](https://holderbook.com/stocks/IMVT/) | $5.8M | 149,524 | 1.1% | 12 |
| INOGEN INC | [INGN](https://holderbook.com/stocks/INGN/) | $5.5M | 845,179 | 1.0% | 30 |
| TANDEM DIABETES CARE INC | [TNDM](https://holderbook.com/stocks/TNDM/) | $5.4M | 355,208 | 1.0% | 13 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $5.3M | 101,266 | 1.0% | 9 |
| STOKE THERAPEUTICS INC | [STOK](https://holderbook.com/stocks/STOK/) | $4.3M | 130,875 | 0.8% | 10 |
| ALLOGENE THERAPEUTICS INC | [ALLO](https://holderbook.com/stocks/ALLO/) | $4.2M | 2,000,000 | 0.8% | 9 |
| BIOCRYST PHARMACEUTICALS INC | [BCRX](https://holderbook.com/stocks/BCRX/) | $4.0M | 400,248 | 0.8% | 15 |
| LAKEFRONT BIOTHERAPEUTICS NV | [LKFT](https://holderbook.com/stocks/LKFT/) | $3.9M | 130,175 | 0.7% | 31 |
| ORTHOPEDIATRICS CORP | [KIDS](https://holderbook.com/stocks/KIDS/) | $3.6M | 189,130 | 0.7% | 2 |
| CYBIN INC | [HELP](https://holderbook.com/stocks/HELP/) | $3.4M | 514,061 | 0.6% | 3 |
| RAPPORT THERAPEUTICS INC | [RAPP](https://holderbook.com/stocks/RAPP/) | $3.1M | 75,000 | 0.6% | 4 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $3.1M | 27,000 | 0.6% | 1 |
| PROQR THRAPEUTICS N V | [PRQR](https://holderbook.com/stocks/PRQR/) | $2.8M | 1,530,361 | 0.5% | 14 |
| NEUROGENE INC | [NGNE](https://holderbook.com/stocks/NGNE/) | $2.8M | 89,032 | 0.5% | 9 |
| ADLAI NORTYE LTD | [ANL](https://holderbook.com/stocks/ANL/) | $2.8M | 239,553 | 0.5% | 1 |
| PROCEPT BIOROBOTICS CORP | [PRCT](https://holderbook.com/stocks/PRCT/) | $2.7M | 120,000 | 0.5% | 3 |
| AQUESTIVE THERAPEUTICS INC | [AQST](https://holderbook.com/stocks/AQST/) | $2.7M | 645,915 | 0.5% | 10 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $2.5M | 68,518 | 0.5% | 4 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $2.5M | 46,500 | 0.5% | 9 |
| ALIGN TECHNOLOGY INC | [ALGN](https://holderbook.com/stocks/ALGN/) | $2.4M | 14,000 | 0.5% | 7 |
| VIKING THERAPEUTICS INC | [VKTX](https://holderbook.com/stocks/VKTX/) | $2.3M | 59,516 | 0.4% | 31 |
| NERVGEN PHARMA CORP | [NGEN](https://holderbook.com/stocks/NGEN/) | $2.2M | 1,050,000 | 0.4% | 1 |
| BIOHAVEN LTD | [BHVN](https://holderbook.com/stocks/BHVN/) | $2.0M | 137,593 | 0.4% | 16 |
| MAZE THERAPEUTICS INC | [MAZE](https://holderbook.com/stocks/MAZE/) | $1.9M | 65,000 | 0.4% | 2 |
| ALECTOR INC | [ALEC](https://holderbook.com/stocks/ALEC/) | $1.8M | 908,351 | 0.3% | 20 |
| LEXEO THERAPEUTICS INC | [LXEO](https://holderbook.com/stocks/LXEO/) | $1.8M | 377,059 | 0.3% | 8 |
| PROFOUND MED CORP | [PROF](https://holderbook.com/stocks/PROF/) | $1.7M | 260,360 | 0.3% | 3 |
| ATRIUM THERAPEUTICS INC | [RNA](https://holderbook.com/stocks/RNA/) | $1.7M | 128,000 | 0.3% | 1 |
| ANNEXON INC | [ANNX](https://holderbook.com/stocks/ANNX/) | $1.7M | 297,812 | 0.3% | 3 |
| CYTOMX THERAPEUTICS INC | [CTMX](https://holderbook.com/stocks/CTMX/) | $1.6M | 438,407 | 0.3% | 2 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $1.6M | 47,100 | 0.3% | 3 |
| EUPRAXIA PHARMACEUTICALS INC | [EPRX](https://holderbook.com/stocks/EPRX/) | $1.5M | 225,600 | 0.3% | 1 |
| DESIGN THERAPEUTICS INC | [DSGN](https://holderbook.com/stocks/DSGN/) | $1.5M | 102,600 | 0.3% | 1 |
| FATE THERAPEUTICS INC | [FATE](https://holderbook.com/stocks/FATE/) | $1.4M | 525,000 | 0.3% | 3 |
| MEDIWOUND LTD | [MDWD](https://holderbook.com/stocks/MDWD/) | $1.4M | 94,405 | 0.3% | 15 |
| KURA ONCOLOGY INC | [KURA](https://holderbook.com/stocks/KURA/) | $1.3M | 120,568 | 0.3% | 31 |
| ARS PHARMACEUTICALS INC | [SPRY](https://holderbook.com/stocks/SPRY/) | $1.3M | 164,285 | 0.3% | 4 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $1.2M | 44,490 | 0.2% | 11 |
| IMMATICS N.V | [IMTX](https://holderbook.com/stocks/IMTX/) | $1.2M | 116,960 | 0.2% | 11 |
| TELA BIO INC | [TELA](https://holderbook.com/stocks/TELA/) | $1.1M | 1,441,029 | 0.2% | 7 |
| POLYPID LTD | [PYPD](https://holderbook.com/stocks/PYPD/) | $1.1M | 207,900 | 0.2% | 10 |
| CORBUS PHARMACEUTICALS HLDGS | [CRBP](https://holderbook.com/stocks/CRBP/) | $1.0M | 107,773 | 0.2% | 1 |
| INSPIRE MED SYS INC | [INSP](https://holderbook.com/stocks/INSP/) | $811.9K | 18,200 | 0.2% | 4 |
| ADICET BIO INC | [ACET](https://holderbook.com/stocks/ACET/) | $810.5K | 93,812 | 0.2% | 3 |
| SEAPORT THERAPEUTICS INC | [SPTX](https://holderbook.com/stocks/SPTX/) | $703.7K | 32,400 | 0.1% | 1 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $651.9K | 11,809 | 0.1% | 4 |
| BIONTECH SE | [BNTX](https://holderbook.com/stocks/BNTX/) | $651.4K | 7,000 | 0.1% | 8 |
| ARTIVA BIOTHERAPEUTICS INC | [ARTV](https://holderbook.com/stocks/ARTV/) | $650.9K | 67,101 | 0.1% | 1 |
| PLIANT THERAPEUTICS INC | [PLRX](https://holderbook.com/stocks/PLRX/) | $555.2K | 487,000 | 0.1% | 2 |
| SCYNEXIS INC | - | $553.0K | 135,868 | 0.1% | 1 |
| EDITAS MEDICINE INC | [EDIT](https://holderbook.com/stocks/EDIT/) | $552.3K | 170,470 | 0.1% | 1 |
| ORCHESTRA BIOMED HLDGS INC | [OBIO](https://holderbook.com/stocks/OBIO/) | $547.3K | 126,841 | 0.1% | 4 |
| FOGHORN THERAPEUTICS INC | [FHTX](https://holderbook.com/stocks/FHTX/) | $545.9K | 111,859 | 0.1% | 9 |
| ACCURAY INC DEL | [ARAY](https://holderbook.com/stocks/ARAY/) | $433.2K | 1,680,508 | 0.1% | 29 |
| Q32 BIO INC | [QTTB](https://holderbook.com/stocks/QTTB/) | $419.1K | 32,896 | 0.1% | 1 |
| NUVECTIS PHARMA INC | [NVCT](https://holderbook.com/stocks/NVCT/) | $367.8K | 20,000 | 0.1% | 1 |
| COMPUGEN LTD | [CGEN](https://holderbook.com/stocks/CGEN/) | $360.0K | 168,232 | 0.1% | 26 |
| IBIO INC | [IBIO](https://holderbook.com/stocks/IBIO/) | $297.6K | 170,053 | 0.1% | 2 |
| AUTOLUS THERAPEUTICS LTD | [AUTL](https://holderbook.com/stocks/AUTL/) | $286.9K | 179,316 | 0.1% | 18 |
| BICYCLE THERAPEUTICS PLC | [BCYC](https://holderbook.com/stocks/BCYC/) | $273.4K | 64,492 | 0.1% | 18 |
| TENAYA THERAPEUTICS INC | [TNYA](https://holderbook.com/stocks/TNYA/) | $221.7K | 300,000 | 0.0% | 1 |
| VERRICA PHARMACEUTICALS INC | [VRCA](https://holderbook.com/stocks/VRCA/) | $145.3K | 23,750 | 0.0% | 3 |
| Engene Therapeutics Inc | [ENGN](https://holderbook.com/stocks/ENGN/) | $129.1K | 74,650 | 0.0% | 1 |
| KARDIGAN INC | [KARD](https://holderbook.com/stocks/KARD/) | $119.2K | 5,000 | 0.0% | 1 |
| ADC THERAPEUTICS SA | [ADCT](https://holderbook.com/stocks/ADCT/) | $82.5K | 77,081 | 0.0% | 9 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +30.2% | +14.8% | +15.4% | 93% |
| Q1 2026 | +3.9% | -4.6% | +8.6% | 98% |
| Q4 2025 | +19.2% | +2.4% | +16.8% | 99% |
| Q3 2025 | +31.3% | +7.8% | +23.5% | 98% |
| Q2 2025 | +6.1% | +10.5% | -4.3% | 98% |
| Q1 2025 | -13.3% | -4.6% | -8.7% | 99% |
| Q4 2024 | -11.2% | +2.1% | -13.3% | 99% |
| Q3 2024 | +5.9% | +5.4% | +0.5% | 97% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $524.4M | 88 |
| Q1 2026 | $439.6M | 83 |
| Q4 2025 | $430.5M | 77 |
| Q3 2025 | $404.8M | 75 |
| Q2 2025 | $362.3M | 76 |
| Q1 2025 | $352.7M | 83 |
| Q4 2024 | $393.4M | 82 |
| Q3 2024 | $423.3M | 84 |
| Q2 2024 | $418.6M | 83 |
| Q1 2024 | $439.3M | 72 |
| Q4 2023 | $417.3M | 76 |
| Q3 2023 | $321.5M | 75 |